You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
Jean-Laurent Casanova, MD, PhD, is the Levy Family Professor and Head of the St. Giles Laboratory at the Rockefeller University, Senior Attending Physician at the Rockefeller University Hospital, and Investigator at the Howard Hughes Medical Institute. He is a pediatrician and immunologist by training, and in practice, has become an internationally renowned human geneticist investigating infectious diseases. Dr. Casanova discovered that life-threatening infectious diseases from childhood may be caused by single-gene inborn errors of immunity, while the same infections in adults can be caused by autoantibodies disrupting the same physiological mechanisms.
Dr. Casanova was elected to the European Molecular Biology Organization in 2005 and to the National Academy of Medicine and the National Academy of Sciences of the United States in 2015. He has also received numerous awards throughout his career, including the Professor Lucien Dautrebande Pathophysiology Foundation Prize (2004), Richard Lounsbery Award (2008), E. Mead Johnson Award from the Society for Pediatric Research (2010), InBev Baillet-Latour Health Prize (2011), Ilse and Helmut Wachter Foundation Award (2012), Milstein Award (2012), Robert Koch Prize (2014), Sanofi-Institut Pasteur Award (2014), Stanley J. Korsmeyer Award (2016), and the Abarca Prize (2021).
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, is a tenured Professor of Medicine in the Department of Infectious Diseases, Infection Control, and Employee Health at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly completed his training in infectious diseases and medical microbiology at the Cleveland Clinic Foundation in Cleveland, Ohio. He is board certified in internal medicine/infectious diseases, medical quality, and medical microbiology.
During his fellowship, Dr. Chemaly completed a master’s degree in public health from Northeastern Ohio Universities in Rootstown, Ohio. In addition to Dr. Chemaly’s clinical research work in virology and multidrug-resistant organisms, he is the Chief Infection Control Officer at the University of Texas MD Anderson Cancer Center, the Chair of the Infection Control Committee, and the past Chair of the Quality and Safety Council of the Division of Internal Medicine. In addition, he is one of the founding members and a past Chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Transplant and Cellular Therapy (ASTCT).
Dr. Chemaly has devoted his career to studying viral infections in immunocompromised patients, specifically those undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies. He has published extensively on mechanisms to treat and prevent viral infections in this population. During his tenure at MD Anderson Cancer Center, Dr. Chemaly established the clinical virology research program and assembled a research team that conducts phase II and phase III clinical trials for new antiviral drugs, which are desperately needed for immunocompromised patients, in addition to principal investigator-initiated trials and lab protocols. He has led and successfully completed more than 20 international and national clinical trials as well as several studies focusing on diagnosis and management of viral infections, the data from which have been presented nationally and internationally with subsequent publications in high-impact journals. Dr. Chemaly has distinguished himself as an outstanding research leader of infectious diseases. He has produced high-quality research that has had a great impact on preventing and appropriately managing infections (particularly viral infections) in immunocompromised patients. Dr. Chemaly’s work has been reported in numerous peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Infectious Diseases, and Clinical Infectious Diseases.
Dr. Chemaly is well known on national and international stages as an expert in clinical and translational virology in immunocompromised hosts. He contributed to writing and updating practice guidelines for respiratory viruses, including SARS-CoV-2, in leukemia and HCT and cellular therapy patients, for three major professional societies: the American Society for Transplantation and Cellular Therapy (ASTCT), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the 8th European Conference on Infections in Leukemia (ECIL 8). In 2019, Dr. Chemaly was elected as a Co-Chair of the Infection and Immune Reconstitution Working Committee of the ASTCT/Center for International Blood and Marrow Transplant Research (CIBMTR) and as a member of the international CMV Forum, which includes representatives from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as experts from national and international academic centers and industry. Dr. Chemaly was elected as an executive member of the Council of the International Immunocompromised Host Society (ICHS) and the Chair of the ESCMID Study Group for Respiratory Viruses (ESGREV).
Ann R. Falsey, MD, is a Professor of Medicine at the University of Rochester School of Medicine. The focus of her research has been clinical and translational research in the field of respiratory viral infections in adults. Dr. Falsey received her Bachelor of Science degree in Biology at Providence College and her Doctor of Medicine degree at Vanderbilt University School of Medicine. She completed her residency in Internal Medicine at Strong Memorial Hospital at the University of Rochester and her infectious disease fellowship at Yale University and the University of Rochester. Initially, the focus of her research was defining the epidemiology and impact of respiratory syncytial virus in adult populations. More recently, Dr. Falsey has broadened her research to include numerous viral respiratory pathogens, including influenza, coronaviruses, parainfluenza viruses, and human metapneumovirus. She has conducted numerous adult surveillance and vaccine studies in a variety of settings, including ambulatory older adult clinics, nursing homes, and senior daycare centers. She has extensive experience in the development and performance of diagnostic and serologic assays for influenza and other respiratory viruses, including cell culture, RT-PCR, EIA, and neutralization assays. She is presently the Co-Principal Investigator of the Rochester Vaccine Treatment and Evaluation Unit and conducts vaccine and therapeutic studies against SARS CoV-2.
Erwin W. Gelfand, MD, is Emeritus Professor of Pediatrics and Immunology at the University of Colorado School of Medicine and National Jewish Health in Denver, Colorado. For almost four decades, Dr. Gelfand has enjoyed the ability to combine interests in clinical susceptibility to disease and the diagnosis and treatment of immune deficiency and allergic diseases. Born in Montreal, Dr. Gelfand received his medical school degree (MDCM) from McGill University. Subsequently, he received his pediatric training at Children’s Hospital in Boston with a Fellowship in Immunology there and from Harvard University. He is board certified in Pediatrics and a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCP-C).
At National Jewish Health, where he was Chairman of Pediatrics for 30 years, and as a Professor of Immunology and Pediatrics at the University of Colorado School of Medicine, Dr. Gelfand directed a major national referral center for patients with uncontrolled atopic disease and immune disorders. During this time, it became increasingly clear to Dr. Gelfand that patients with severe atopic disease, especially atopic dermatitis, may harbor a significant monoallelic mutation in an immune system pathway gene. In this way, immune deficiency diseases can masquerade as an allergic disease. Dr. Gelfand carried out some of the earliest bone marrow transplants in patients with immune deficiency and was a leader in the use of immunoglobulin therapy, not only in immunodeficiency, but also in autoimmune and inflammatory conditions.
With training as an immunologist, Dr. Gelfand’s interests are focused on unique diseases where genetic evaluation holds the key. He has published more than 800 articles in leading peer-reviewed journals including Science, Cell, Nature, Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, and the New England Journal of Medicine. He is the recipient of continuous grant support from the National Institutes of Health and numerous prestigious awards. Perhaps most importantly, he has trained more than 100 postdoctoral fellows in his laboratory, with many going on to be leaders internationally and in their own countries.
Michael David Green, MD, MPH, is Professor of Pediatrics, Surgery, and Clinical and Translational Science at the University of Pittsburgh School of Medicine (UPMC). He is the Medical Director of Infection Prevention and Antimicrobial Stewardship at UPMC Children’s Hospital of Pittsburgh. He also serves as Co-Director, Transplant Infectious Diseases in the Division of Pediatric Infectious Diseases.
Dr. Green received his Bachelor of Science degree from the University of Illinois-Urbana Champaign and his Doctor of Medicine degree from the University of Illinois in Chicago. He also holds a Master of Public Health degree in Infectious Diseases Epidemiology from the University of Pittsburgh. He completed a pediatric residency and a fellowship in pediatric infectious diseases at Children’s Hospital of Pittsburgh before joining the faculty at the University of Pittsburgh School of Medicine.
Throughout his career, Dr. Green’s clinical and research interests have focused on the prevention and treatment of infections in immunocompromised children. Dr. Green is a member of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the International Pediatric Transplant Association, and the American Society of Transplantation, where he served as a Councilor-at-Large and Secretary-Treasurer. Dr. Green has published more than 160 peer-reviewed articles and has written more than 70 review articles or textbook chapters. He serves as an Associate Editor for Pediatric Transplantation, the American Journal of Transplantation, and the Journal of the Pediatric Infectious Diseases Society. He was also Co-Editor of the first edition and, more recently, Editor-in-Chief of the 4th edition of the Guidelines for the Prevention and Management of Infectious Complications of Solid Organ Transplantation, published by the American Society of Transplantation. He has participated in numerous Consensus Conference and Guideline working groups relating to the field of transplant infectious diseases and is a past Chair of the International Pediatric Transplant Association (IPTA) Infectious Disease Care Committee and the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Ad Hoc Disease Transmission Advisory Committee. An active teacher and clinical researcher, Dr. Green has consistently received grant funding for his work since 1987.
Jordan Scott Orange, MD, PhD, is the Chair of Pediatrics at Columbia University Vagelos College of Physicians and Surgeons. Dr. Orange was previously at Baylor College of Medicine, where he was Vice Chair for Research in Pediatrics, Director of the Pediatrician-Scientist Training and Development Program, and Chief of Immunology, Allergy, and Rheumatology. At Texas Children's Hospital, Dr. Orange held the Louis and Marybeth Pawleek Endowed Chair and was Director of the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency and of the Center for Human Immunobiology.
An international leader in pediatric primary immunodeficiency and the immunobiology of human natural killer cells, in his research Dr. Orange combines novel disease discovery with basic cell research to translate underlying biological mechanisms of disease into clinical applications. His research has been continuously funded by the National Institutes of Health, and he has published over 350 papers. Dr. Orange is a member of the American Society for Clinical Investigation and the American Pediatric Society. He is a recipient of the E. Mead Johnson Award for research accomplishment in pediatrics from the Society for Pediatric Research. In 2018, he was elected into the National Academy of Medicine.
Dr. Orange received his AB, PhD, and MD degrees from Brown University and went on to residency training at Children's Hospital of Philadelphia, a clinical fellowship at Boston Children's Hospital, and a postdoctoral research fellowship at Harvard.